Background Interstitial lung disease in systemic sclerosis (SSc-ILD) is a major cause of SSc-
related death. Imunosuppressive treatment (IS) is used in patients with SSc for various organ …

Objectives To identify overall disease course, progression patterns and risk factors
predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis …

Interstitial lung disease (ILD) affects about 90% of patients with systemic sclerosis (SSc). It is
associated with a restrictive lung disease in only 30% of patients and is progressive in an …

Objectives To investigate prevalence estimates and incidence rates (IRs) for SSc and SSc-
associated interstitial lung disease (SSc-ILD) cohorts and describe patient characteristics …

Objective Interstitial lung disease (ILD) is a leading cause of mortality in SSc. Little is known
about the benefits of immunosuppressive drugs in mild ILD. Our aim was to determine …

Objective To evaluate the effects and safety of 6-month intravenous cyclophosphamide
(CYC) followed by 18-month oral azathioprine (AZA) therapy in patients with systemic …

Systemic sclerosis (SSc; scleroderma) has the highest individual mortality of all rheumatic
diseases, and interstitial lung disease (ILD) is among the leading causes of SSc‐related …

This systematic review summarises current evidence to help guide treatment decisions for
patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD). A systematic …

Objective To assess survival and identify predictors of survival in patients with systemic
sclerosis-interstitial lung disease (SSc-ILD) who participated in the Scleroderma Lung …

Treatment for systemic sclerosis-associated interstitial lun... : Current Opinion in
Rheumatology Treatment for systemic sclerosis-associated interstitial lung disease : Current …